Literature DB >> 7517642

H(+)-ATPases of renal cortical and medullary endosomes are differentially sensitive to Sch-28080 and omeprazole.

I Sabolić1, D Brown, J M Verbavatz, J Kleinman.   

Abstract

Adenosinetriphosphatase (ATPase) activity stimulated by K+ and inhibited by Sch-28080 (SCH), omeprazole (OME), and vanadate has been measured in microsomes from mammalian renal medulla and attributed to a kidney isoform of the H(+)-K(+)-ATPase. To determine whether the H(+)-K(+)-ATPase inhibitors could also inhibit the vacuolar (V)-type H(+)-adenosinetriphosphatase (H(+)-ATPase, i.e., H+ pump) in mammalian intracellular vesicles, we examined their effects on bafilomycin-sensitive acidification in renal cortical vesicles (CEV) and medullary endocytic vesicles (MEV). Rats were injected with fluorescein isothiocyanate-labeled dextran, and labeled endosomes were enriched from kidney tissue homogenates by differential and Percoll density gradient centrifugation. In the CEV, the V-type H+ pump was inhibited 25% by SCH and 30% by OME (100 microM each). Whereas the inhibition by OME was concentration and time dependent, the inhibition by SCH was only concentration dependent. Inhibition by these compounds was similar in the presence of 50 mM K+ (in = out) and in the complete absence of K+, thus ruling out a significant involvement of H(+)-K(+)-ATPase-mediated acidification. Inhibition, however, was not observed with 10 microM SCH and OME. The sensitivity of the V-type H+ pump to 100 microM SCH and OME in CEV was confirmed by the comparable inhibitions of intravesicular acidification observed in acridine orange fluorescence quench studies and by inhibition of Pi liberation in an ATPase assay. We also found that the V-type H+ pump in isolated rat liver endosomes is sensitive to 100 microM SCH and OME to a similar degree. In the MEV, acidification was only weakly affected by 100 microM SCH and OME, thus suggesting that H(+)-ATPases in endosomes from cortical and medullary tubules are different, possibly due to a previously described selective expression of subunit isoforms. Our finding indicates the importance of using low concentrations (< 10 microM) of OME and SCH in studies of H(+)-K(+)-ATPase in nongastric tissues to avoid misinterpretation of the data due to nonspecific inhibition of V-type H(+)-ATPases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517642     DOI: 10.1152/ajprenal.1994.266.6.F868

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  12 in total

1.  Proton pump inhibitors have pH-dependent effects on the thermostability of the carboxyl-terminal domain of voltage-gated proton channel Hv1.

Authors:  Qing Zhao; Weiyan Zuo; Shangrong Zhang; Yongqiang Zhang; Chuanyong Li; Shu Jie Li
Journal:  Eur Biophys J       Date:  2017-09-09       Impact factor: 1.733

2.  Omeprazole-induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype.

Authors:  Nuala A Helsby; Wing-Yee Lo; Ian J Simpson; David M Voss; Kaye E Logan; Martin Searle; John B W Schollum; Janak R de Zoysa
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

3.  A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin.

Authors:  Irene Brana; Alberto Ocana; Eric X Chen; Albiruni R A Razak; Christine Haines; Carol Lee; Sarah Douglas; Lisa Wang; Lillian L Siu; Ian F Tannock; Philippe L Bedard
Journal:  Invest New Drugs       Date:  2014-09-12       Impact factor: 3.850

4.  Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer.

Authors:  Jin-Liang Zhang; Min Liu; Qing Yang; Shi-Yong Lin; Hong-Bo Shan; Hui-Yun Wang; Guo-Liang Xu
Journal:  World J Gastroenterol       Date:  2017-04-14       Impact factor: 5.742

Review 5.  Vacuolar ATPase as a potential therapeutic target and mediator of treatment resistance in cancer.

Authors:  Bradleigh Whitton; Haruko Okamoto; Graham Packham; Simon J Crabb
Journal:  Cancer Med       Date:  2018-06-21       Impact factor: 4.452

6.  Proton Pump Inhibitors Reduce Pancreatic Adenocarcinoma Progression by Selectively Targeting H+, K+-ATPases in Pancreatic Cancer and Stellate Cells.

Authors:  Marco Tozzi; Christiane E Sørensen; Lara Magni; Nynne M Christensen; Rayhana Bouazzi; Caroline M Buch; Matteo Stefanini; Claudia Duranti; Annarosa Arcangeli; Ivana Novak
Journal:  Cancers (Basel)       Date:  2020-03-10       Impact factor: 6.639

Review 7.  The H+-ATPase (V-ATPase): from proton pump to signaling complex in health and disease.

Authors:  Amity F Eaton; Maria Merkulova; Dennis Brown
Journal:  Am J Physiol Cell Physiol       Date:  2020-12-16       Impact factor: 4.249

8.  Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors.

Authors:  Man Yu; Carol Lee; Marina Wang; Ian F Tannock
Journal:  Cancer Sci       Date:  2015-09-25       Impact factor: 6.716

9.  Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer.

Authors:  Taejong Song; Hye-Kyung Jeon; Ji Eun Hong; Jung-Joo Choi; Tae-Joong Kim; Chel Hun Choi; Duk-Soo Bae; Byoung-Gie Kim; Jeong-Won Lee
Journal:  Cancer Res Treat       Date:  2016-09-27       Impact factor: 4.679

10.  Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors.

Authors:  Chaitra Prabhakara; Rashmi Godbole; Parijat Sil; Sowmya Jahnavi; Shah-E-Jahan Gulzar; Thomas S van Zanten; Dhruv Sheth; Neeraja Subhash; Anchal Chandra; Akshatha Shivaraj; Patricia Panikulam; Ibrahim U; Vijay Kumar Nuthakki; Theja Parassini Puthiyapurayil; Riyaz Ahmed; Ashaq Hussain Najar; Sai Manoz Lingamallu; Snigdhadev Das; Bhagyashri Mahajan; Praveen Vemula; Sandip B Bharate; Parvinder Pal Singh; Ram Vishwakarma; Arjun Guha; Varadharajan Sundaramurthy; Satyajit Mayor
Journal:  PLoS Pathog       Date:  2021-07-12       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.